Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab.

Literature DB >> 30936058

Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab.

Catherine Lai¹, Vishal Ranpura¹, Colin Wu¹, Matthew J Olnes¹, Ankur R Parikh¹, Aarthi Shenoy¹, Julie Thompson¹, Barbara Weinstein¹, Phillip Scheinberg¹, A John Barrett¹, Ronan Desmond¹, Neal S Young¹, Christopher S Hourigan¹.

Abstract

Entities: Chemical Disease Species

Year: 2019 PMID： 30936058 PMCID： PMC6457214 DOI： 10.1182/bloodadvances.2018030411

Source DB: PubMed Journal: Blood Adv ISSN： 2473-9529

× No keyword cloud information.

15 in total

1. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.

Authors: Elaine M Sloand; Matthew J Olnes; Aarthie Shenoy; Barbara Weinstein; Carol Boss; Kelsey Loeliger; Colin O Wu; Kenneth More; A John Barrett; Phillip Scheinberg; Neal S Young
Journal: J Clin Oncol Date: 2010-11-01 Impact factor: 44.544

2. Revised international prognostic scoring system for myelodysplastic syndromes.

Authors: Peter L Greenberg; Heinz Tuechler; Julie Schanz; Guillermo Sanz; Guillermo Garcia-Manero; Francesc Solé; John M Bennett; David Bowen; Pierre Fenaux; Francois Dreyfus; Hagop Kantarjian; Andrea Kuendgen; Alessandro Levis; Luca Malcovati; Mario Cazzola; Jaroslav Cermak; Christa Fonatsch; Michelle M Le Beau; Marilyn L Slovak; Otto Krieger; Michael Luebbert; Jaroslaw Maciejewski; Silvia M M Magalhaes; Yasushi Miyazaki; Michael Pfeilstöcker; Mikkael Sekeres; Wolfgang R Sperr; Reinhard Stauder; Sudhir Tauro; Peter Valent; Teresa Vallespi; Arjan A van de Loosdrecht; Ulrich Germing; Detlef Haase
Journal: Blood Date: 2012-06-27 Impact factor: 22.113

3. International scoring system for evaluating prognosis in myelodysplastic syndromes.

Authors: P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett
Journal: Blood Date: 1997-03-15 Impact factor: 22.113

4. Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A.

Authors: C Kelaidi; T Braun; R Arana; A Marceau-Renaut; G Lazarian; J Soret; S Cereja; R Letestu; V Eclache; D Lusina; F Baran-Marszak; L Ades; C Preudhomme; A Martin; P Fenaux; C Gardin
Journal: Leuk Res Date: 2018-05-29 Impact factor: 3.156

5. Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients.

Authors: T Okamoto; M Okada; A Mori; K Saheki; H Takatsuka; H Wada; A Tamura; Y Fujimori; Y Takemoto; A Kanamaru; E Kakishita
Journal: Int J Hematol Date: 1997-10 Impact factor: 2.490

6. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort.

Authors: Maximilian Stahl; Michelle DeVeaux; Theo de Witte; Judith Neukirchen; Mikkael A Sekeres; Andrew M Brunner; Gail J Roboz; David P Steensma; Vijaya R Bhatt; Uwe Platzbecker; Thomas Cluzeau; Pedro H Prata; Raphaël Itzykson; Pierre Fenaux; Amir T Fathi; Alexandra Smith; Ulrich Germing; Ellen K Ritchie; Vivek Verma; Aziz Nazha; Jaroslaw P Maciejewski; Nikolai A Podoltsev; Thomas Prebet; Valeria Santini; Steven D Gore; Rami S Komrokji; Amer M Zeidan
Journal: Blood Adv Date: 2018-07-24

7. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy.

Authors: Elaine M Sloand; Colin O Wu; Peter Greenberg; Neal Young; John Barrett
Journal: J Clin Oncol Date: 2008-04-14 Impact factor: 44.544

8. Real life experience with alemtuzumab treatment of patients with lower-risk MDS and a hypocellular bone marrow.

Authors: Judith Neukirchen; Uwe Platzbecker; Katja Sockel; Antonis Tsamaloukas; Rainer Haas; Ulrich Germing
Journal: Ann Hematol Date: 2013-08-10 Impact factor: 3.673

9. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin.

Authors: Z Y Lim; S Killick; U Germing; J Cavenagh; D Culligan; A Bacigalupo; J Marsh; G J Mufti
Journal: Leukemia Date: 2007-05-17 Impact factor: 11.528